ACR 2026 RheumNow RA Topic Compilation b Save
JAKi Cardiovascular Safety in Younger Adults
Four Joint Fibromyalgia Warning
Difficult to Treat RA
Use of JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease
Good News and Bad News for CCP+ at Risk for RA
Combination Therapy in Rheumatoid Arthritis
Snippets & SNPs in ILD and Fibrosis
CAR-T in Rheumatoid Arthritis will it stay
Not Seronegative Rheumatoid Arthritis-Interstitial Lung Disease
What Happens to Muscle Mass and Muscle Strength in RA
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to roomnow.live to see the full program and register today.
David Lu here as part of RheumNow's rheumatoid arthritis coverage from ACR convergence twenty six. I wanted to point out a poster, on the poster floor which looks at TriNetX data. And immediately when people say that nowadays, everyone gets a bit cautious, but I think this has been done quite well. And it really addresses a point that, has sometimes been missing from the discussion. What is that?
Well, it's about JAK inhibitor safety in younger adults. One of the real victims of, any loss of nuance around ace... Around, oral surveillance has been what happens to younger adults who might benefit from JAK inhibitors and the discussions, the nuances of discussions around starting a JAK inhibitor. And, you worry that, people might not be getting the best therapies that they could be because these conversations are difficult to navigate from many different directions. So this is exactly what this analysis looks at.
It looks at these big data, but looks at younger adults, 18 to 64, with rheumatoid arthritis starting therapy compares JAK inhibitors to TNF inhibitors, looks at cardiovascular outcomes, some new major adverse cardiovascular events, arterial cardiovascular events, VTEs, and and tries to see whether there's any signal there knowing that we haven't always seen our observations replicated in observational data. But what's very clear here is that there is no signal in younger adults, as far as this is concerned. So I think what what do we take away from that? And and look. There's some nuances with the data that I'm not gonna drag you through, but just to say that I think as much of the discussion has been there's been debate within the enriched, at risk population that oral surveillance targeted in terms of JAK inhibitor safety.
And, you know, that is... That's been well documented. Outside of that, and realistically, when you break down oral surveillance, outside of the patients who have actually had outright cardiovascular events in the past, you have to say that the risk is, very close to that what... In what you see with TNF inhibitors. And we've got to be very cautious about not disadvantaging those types of patients away from effective therapies knowing that we should keep the nuance, keep the balance and be aware of what the regulatory warning does show.
So for lots more on rheumatoid arthritis, you know where to go. Roomnow.com.
Hi. This is Bella Mehta from RoomNow reporting from ACR twenty six. I came across an interesting abstract. Abstract number 0616. What it's trying to do is figure out if patients with RA who also have fibromyalgia, are there certain things that can help us find these patients who have additional pain or additional symptoms which are consistent with fibromyalgia?
So, know, the fibromyalgia nineteen ninety criteria is much more restrictive than the twenty sixteen criteria. So more patients are now getting diagnosed because of the slightly more relieved criteria. So what these investigators did was try to figure out if, you know, making a... Or finding a difference between tender joint minus swollen joint, if that helps us distinct or find these patients. So back in the day, there was a study looking at this threshold of tender minus swollen joints, it was seven...
If there's seven joints which are more tender than just the swollen joints, that seemed to be something that can help figure out help figure out if patients have fibromyalgia. So, they now use the twenty sixteen criteria and, try to figure out if, patients... What's the difference in the tender and swollen joint count. So when they did that, around, you know, seven percent more patients were diagnosed with fibromyalgia using the slightly broader criteria. So it was twenty two percent in the nineteen ninety criteria versus twenty nine percent in the twenty sixteen criteria.
And, again, these are all RA patients who have an additional diagnosis of fibromyalgia with the new criteria. They also found that when the threshold of four, you know, tender minus swollen joint count, the threshold of four was applied, the sensitivity increased from point seven one to point seven six. But the specificity did go down from around, again, point seven to around 4.58. So what it tells me is that, again, we all know that when somebody has many, many tender joints, there's a high likelihood of central pain or fibromyalgia or one of those things. But this study gives you a rough sort of estimate or a rough thing that you can go off saying, if it's more than four, the difference in joint count for tender and swollen, you sort of wanna think if there is, you know, if there is another component to it.
Is this a definite checkpoint? Absolutely not. But it's something to help you start thinking about this. So, I I think, it's important for clinicians to take home that four four joint counts threshold, which is more tender than swollen, is helpful to find other pain syndromes, including fibromyalgia. With that, signing off.
This is Bella Mehta on RheumNow, and follow us more on Twitter, Bella underscore Mehta. Thank you.
Hi. It's doctor Arti Kavanagh from University of California San Diego coming to you for RheumNow. And I'm here at the ACR Convergence. First day of the meeting, really a packed meeting with a lot of great information already and a lot more to come still. A topic I'm going to talk about, and we're talking about themes, we're talking about just principles, to treat rheumatoid arthritis.
And the reason I picked this topic, well, it's a hot topic, and I think we've seen a lot more interest in this. We're talking about newer therapies, newer treatments, newer treatment algorithms for rheumatoid arthritis. Some of them, if you think of the risk benefit ratio, maybe they're a little bit riskier. So, would you want to have it for a population of patients where there's the greatest need? And as clinicians, I think we think maybe the greatest need is in the most refractory patients.
We've known forever in rheumatoid arthritis care that the more therapies you have tried, the more therapies you have failed, the more refractory you are. The less well you're going to do with the fifth therapy if you have been on four. We've known that since the days of just conventional synthetic DMARDs. What about now? What do we know about this?
Difficult to treat rheumatoid arthritis, the EULAR group has come up with a definition of that, which you can look up. It makes sense. It's a difficult concept, I think, for us clinicians. We all know the patients that we see in the clinic who are difficult to treat. We can identify them, but it's hard to write that down.
So what is this difficult to treat? There's an abstract, fourteen oh seven, which looked at this with an interesting side take, I believe, and that is we talk about difficult to treat RA. Well, how stable is that? What happens to people if you go to the clinic and you find a bunch of people who are classified as difficult to treat RA using the UR criteria? What happens to them over time?
So they looked at this in this abstract, and what they found was relevant to people who were interested in coming up with treatment algorithms and therapeutic studies for difficult to treat RA. What they found is about half the patients seemed to be stable in difficult to treat RA, meaning they were difficult to treat RA at subsequent time points. The other half were less stable. Some jerked right out, they were not in difficult to treat anymore. Some came in and out to various degrees.
Interesting question. If you were planning to treat difficult to treat RA patients, who would you pick? I think the first blush you might say, well, the ones who are in difficult to treat all the time, because they're the toughest, they're the most refractory, but maybe they're the ones more likely to be influenced by things like pain, and they may never respond to immunomodulatory therapies. But if you have those who come in and out, and the investigators looked at this, treatment didn't necessarily relate to them coming in and out difficult to treat. So, fascinating question.
It's one of those things that we all know what difficult to treat means when we go to the clinic, but how do you translate that into something where you can write it down and put it into a clinical trial? This is Doctor. Arti Kavanaugh coming to you from ACR Convergence twenty twenty six for RheumNow.
Hello. My name is Elena Jerns, and I'm reporting from Orlando, Florida. A lot of interest in JAK inhibitors in RA ILD at this meeting. I'm glad to see the studies because we certainly need more. It does seem that JAK inhibitors are helpful in our reality based on a small meta analysis which was published in 2024.
But we have so many JAK inhibitors now and we are often limited by insurance companies in what we can prescribe. But are they truly interchangeable? Are they truly safe and efficacious in our ALD? Well, this meeting had several relevant posters. So poster number four seventy eight by doctor Munoz detailed results of a retrospective observational study of baricitinib in eighty four patients with RAILD.
They demonstrated stability of PFTs and improvement in dyspnea throughout follow-up, and importantly the steroid use was decreased. We of course don't know how their trajectory was prior to the treatment from the abstract, but the improvement in symptoms and reduction in steroids is encouraging regardless. Poster number four forty nine by Doctor. Kikuchi and colleagues also demonstrated that the array ILD was stable and even improved based on lung ultrasound scores with treatment with JAK inhibitors. They didn't specify the JAK inhibitors, unfortunately.
In poster seven zero three, Doctor. Ortiz and colleagues looked at 43 patients from Spain treated with upadacitinib and found stability or improvement in lung function parameters and again symptoms of dyspnea. Despite these promising results, JAK inhibitors are still not widely used in our RAYALDEE as per poster number four two by Doctor. Sarmiento Monroy regarding real world treatment patterns in Array ILD. Their nested case control study from Spain showed that only three percent of patients with Array ILD were treated with JAK inhibitors, but eleven percent of patients with RA with no ILD at baseline were treated with JAK inhibitors.
Important safety signal for JAK inhibitor was accessed. I think the worry about cardiovascular safety precludes us often from prescribing JAK inhibitors in RA LD, as these patients are frequently dosed with many cardiovascular risk factors also. Poster number four forty one by Doctor. Kasiraj compared safety between JAK inhibitors and found that tofacitinib was associated with significantly higher risk compared to upadacitinib or baricitinib in terms of major cardiovascular events. And Doctor.
Kazero's study in poster four forty two found that signal as well tofacitinib but not upadacitinib was associated with higher risk of major cardiovascular events in a real world study. The multitude of studies of JAK inhibitors, and these are not even all the posters about them, support the use of JAK inhibitors in RYALD. Safety signals support going for baricitinib or upadacitinib in patients with RALD who have cardiovascular risk factors. And I would advocate for perhaps a randomized controlled trial, and specifically RALD using specific JAK inhibitors. It does seem like we're not using JAK inhibitors enough in RA ILD yet, but hopefully it'll change with more data.
Thank you.
Hi. It's doctor Janet Pope. I tweet under at Janet Bourdeaux. I'm here at RheumNow reporting on ACR twenty twenty six in Orlando, and it's a great meeting. I wanted to talk about people at risk for RA who are anti CCP positive, who gets RA, and also who might not get RA.
And the latter, patients, maybe we don't even have to follow them for very long. Who knows? So this is... The first abstract was 1834. So, again, this is the Leeds cohort for both of these abstracts.
So what they were doing was CCP positive, and they had MSK pain. So they might have had arthralgia. They might have had other MSK pain, and they were put on a protocol to be followed regularly, including by ultrasound. So a hundred and ninety three of these patients, which there were over four hundred and fifty, of those patients, a third of them had erosions. And by erosions, I mean by ultrasound, not by plain X-ray.
Where were the erosions? The areas that we try to teach you where erosions occur early. Fifth, MTP, lateral side, MCP, especially number two, and wrist. Also, the other area I like to tell patient... Tell trainees about is the owner style, but, distally, but they didn't talk about that one.
But fifth MTP, MCP, especially the second one, and wrist. So what did they find? These people that had an ultrasound erosion, not all of them progressed to clinical diagnosis of rheumatoid arthritis, and not all of them, the erosion stayed because this is ultrasound, not plain X-ray. But if you have these erosions at baseline, one or more, you had more severe RA, you were more apt to need biological DMARDs, and you were more apt to be difficult to treat. Not everyone progressed, and not everyone, got RA in the group that didn't have this either.
So that was the take home. Now the next abstract was, abstract 1835. And what the question here was, in this, pre RA or RA at risk, ACPA positive cohort of patients with, MSK pain, who... What would be the good predictors over the next five to ten years? Who is not gonna get rheumatoid arthritis?
So, again, they have some kind of pain, MSK, and they're CCP positive. They were on the protocol. And if you had, good predictors, three of five, eighty two percent did not progress over the next, five to ten years. There are four hundred and fifty patients followed in this group. So what were the good predictors?
They all were CCP positive. So if your CCP was pretty low, that was better. Negative rheumatoid factor, normal ESR, less than or equal to one tender joint, and no tenosynovitis on clinical or on imaging. So my question is, if I have a patient that has all those good predictors with a positive ACPA, if they had all five of them, none of them in the next five to ten years developed RA. Can I just say, I don't need to see you?
Call me if things change. I think at this point in time, I'd still be more apt to follow them regularly at least for a while, but this is really helpful to predict who will do well over time. Please follow our reporting at RheumNow. Thank you.
Hi. This is doctor Arti Kavanagh coming to you from ACR twenty twenty six Convergence for RheumNow. My perspective this talk is going to be on combination therapy, specifically combination therapy in rheumatoid arthritis. Fascinating topic that has a deep history. Based on the 80s, there were many animal models of rheumatoid arthritis which suggested that combinations of different targeted therapies is probably the way to go.
Thinking of TNF inhibition, IL-one inhibition, in animal models, that was fantastic. You not only saw additive benefit, you saw synergistic benefit. You saw the complete abrogation of inflammation and damage in animal models. Of course, as we all know, in humans the experience was much different. In studies that looked at TNF inhibition plus IL-one inhibition, and TNF inhibition with T cell inhibitor therapy with abetacept, the results were dismal.
There was not clinical benefit, but there was a readout, and that was increased infection. So since that time, and this is now going back to the early nineties, there's been black boxes that say do not combine biologic agents. Well, times are evolving, and thanks to collaboration with our colleagues in ulcerative colitis and a pivotal study called Vega that showed that combination of a TNF inhibitor, glimumab, plus an IL-twenty three inhibitor, gazelkumab, did what we had always hoped combination therapy would do, and that is additive benefit without additive toxicity. Now, rheumatoid arthritis has kind of lagged that a little bit. There are studies going on in ulcerative colitis, in IBD otherwise, in ankylosing spondylitis, in psoriatic arthritis.
Not so far in rheumatoid arthritis. I think we've still been a little bit gunshot. So there are a couple of abstracts at this meeting, small numbers of patients, one from Neuven, which had six RA patients, and this abstract, fourteen oh two, which looked at abetacept plus an anti CD38 monoclonal antibody, daratumumab. Three patients only, severe refractory disease. The results really kind of didn't knock your socks off, even though it's only three patients.
There was an improvement, and they are very refractory patients, and there didn't seem to be a lot of toxicity, but there was some. Daratumumab anti CD38 monoclonal antibody approved for certain kinds of cancer, but it's strong, and it's a strong therapy directed at cells bearing CD38, which is widely spread. Looking at these results, I would say I'm not sure that I'm excited about this particular approach, but I think it's great to see the idea of combination therapy opening up, and I think we're at the point where we'll see anecdotes such as these. In the Leuven study, TNF inhibitors and JAK inhibitors were combined, and it seemed to not have a safety signal. Of course, we need more patients, but I think we'll see that certain combinations get knocked out of the running early, and others need to be studied further in more rigorous study design.
So combination therapy may be coming back in rheumatoid arthritis. This is Doctor. Arti Kavanagh coming to you from ACR twenty twenty six Convergence for RheumNow.
Hi. I'm doctor Janet Pope or tweeting as, at Janet Brudeau. I'm here at RheumNow at ACR twenty twenty six in Orlando, Florida. I wanted to talk about SNPs and snippets in interstitial lung disease related to our SARDs. So I'm gonna talk about three posters, 0019, 0037, and 0025.
And they have some mechanisms of action in common and different pathways. So the first one, zero zero one nine, was looking at t l one a in sarcoidosis and looking at the fibrosis and sarcoidosis, which could be systemically all over, including in the lungs. And t l one a is a target for some, drug trials for pulmonary, interstitial lung disease. So what they found was t l one a was, abnormal in the myeloid cells and eventually in the cells that became and made granuloma. And so it would look like it's something important on causation.
And what they found was t o one a was affecting TNF, I o one beta, I o six, and I o 17. And they're all cytokines you're very familiar with in inflammatory arthritis as a for instance. So I think this might mechanistically give us an idea of upstream and downstream, areas for interstitial lung disease or fibrosis that we might be able to target. The next one was looking at 37, the poster. It was looking at scleroderma ILD and they wanted to look at correlations with baseline FVC, so forced vital capacity.
It was actually FVC percent predicted. So they did a whole array on sixty patients with scleroderma ILD and nineteen with scleroderma, no ILD, and they kinda match those patients. And what they found was predictive at baseline, but not of worsening over time. So both an elevated k... KL six and an abnormal ICAM one were both important for low FVC at the beginning.
However, the holy grail in scleroderma ILD is predicting who might have upregulated things that might actually might actually show that we can predict what's going to happen in scleroderma ILD. The final one was from UCSF, it's 25 and it was looking at some similarities comparing and contrasting SARD ILD and progressive pulmonary fibrosis, IPF. So it's been known to them, and I guess now to me, is that short telomeres are a big deal in, IPF that they're often present, and I think they're correlated with worth... Worse IPF. And some people are even ordering telomeres more for research purposes.
So what they wanted to look at was senescence with epithelial remodeling that would be bad remodeling. And what they found was that DNA damage was quite common patients with ILD and the SARDs, the systemic autoimmune rheumatic diseases, and also in IPF. Why did I choose this poster is because I think it's yet another pathway to say if there's abnormal senescence, is there ways of changing that that we could modify or decrease the chance of someone with SARD ILD going to fibrosis? So I hope these snippets that I, got from posters will be helpful to you in understanding ILD of the SARDs. Thank you.
David Lu here covering ACR conversions 2026, and some very interesting stuff, about Carti and R. A. That's come out at this meeting. It's been perhaps a little less enthusiastic than what we've seen for CAR T and lupus, CAR T and Sjogren... So CAR T and scleroderma, CAR T and and myositis.
But nevertheless, it's understandable that manufacturers are looking at RA. They can see a really big potential market there. They can see that there's an established pathway to therapies. There are already plenty of expensive therapies there and that there are issues and that really it'd be nice to be able to offer people options in RA. Yet at the same time they've got to compete with existing therapies and that's the tough balance of it.
I think one thing which has we've seen, well we've seen we've seen at this meeting but also seen hyped up in general has been actually the COMPARE study which was published in Nature Medicine a couple of months ago but also was back again at this meeting. It's from Germany, not Gaelscheid, but a broader group, only six patients. But I think it gives you an idea about some of the sticking points in trying to navigate this story in rheumatoid arthritis. So firstly, it's conventional CAR T and comes with all the challenges that we see there. Secondly, in order to make it a valuable interpretation of this, it's highly refractory rheumatoid arthritis patients.
You need to have failed at least one biologic actually multiple in practice. And so we're seeing this in the way that studies recruit as well and and I guess that makes it harder to interpret. It's harder to apply our general conventions to this. What are what are we expecting? Maybe that's actually part of the game here that, and to some extent any gain is better.
So anything that gives you efficacy in these tough patients is clearly promising and there's appropriate a lot of interest but you know you break through both what we've seen here and in the paper. Actually you know it's not necessarily going to be the cure. It's not a cure for everyone. It's not it's not a long term panacea for everyone. We're seeing people within the year who get a response and then things bounce back again.
You have to ask yourself how much of that was lymphodepletion? How much of that was something else versus actually true effect. We're seeing a lot of things creep up. I guess some of the other things like antibody titers, it's hard to know how to interpret. So, as we start to see bigger numbers, we're going to start to be able to ask ourselves questions about what type of patients to select.
And that's going to be all well and good. But I think we need to just, at this point in time for rheumatoid arthritis, set appropriate expectations. If we're going to use CAR T in this disease know that it's not going to cure it's not going to be for everyone definitely. The people who it's for it's not necessarily going to cure them all either. We're going have to work through all the same problems with CAR T that we are working through with lupus and scleroderma and myositis.
So for plenty more about RA and plenty more about CAR T, you know where to go. Rheumnow.com.
Hello, everyone. I'm Richard Conway from Dublin, Ireland reporting for RheumNow from ACR twenty twenty six. I'm here to talk to you today about an interesting abstract from Sunday's poster session. This was abstract number four seventy five by Rocolia et al. This study, I'm calling it not seronegative or a ILD, but the actual title is Association of Novel Autobahn Antibodies with ILD and aerosive Disease in Seronegative Rheumatoid Arthritis.
And first of all, that aerosive disease part, I'm not going to talk about it. It wasn't that interesting what they found in that area, in my opinion. But the other half of it was. So seronegative rheumatoid arthritis is a term I am not a huge fan of in general. What we generally mean is it's negative for rheumatoid factor and CCP.
But as we'll see with this study, maybe it's not actually seronegative at all. So to me, it's more like these patients are patients with RA in search of their autoantibody, which we either can't find or don't have availability of the tests which demonstrate us. And rheumatoid arthritis related interstitial lung disease, we know is quite strongly associated with the autoantibody nature of disease, so associations with both rheumatoid factor and CCP. So that being the case, I like the existence of seronegative RA ILD even less. It just doesn't jive right with me.
So as I said, I think generally these patients who have oral ALD and they're negative for rheumatoid factor and CCP, my suspicion is that there probably are other autoantibodies there that we can't pick up yet. And great, these authors have found some. So they included forty eight seronegative rheumatoid arthritis patients. Now there's only ILD in four of those. So we're dealing with a relatively small sample size here, but still I think the results are interesting.
So these authors looked at two novel autoantibodies, what they've termed them. I guess autoantibodies that we don't check as commonly because they're not brand new things. So first of these was anti SA antibody and the second was anti CAR P. And they looked at those antibodies, saw how frequent they were in patients with and without ILD. So anti SA is the interesting one.
So that was positive in forty two point nine percent of patients with ILD and in only two point four percent of those without ILD. So greatly more common in those patients with ILD. The anti CAR P antibodies in contrast were equally present in those with and without ILD being found in eight point three percent of both sets of patients. So that's interesting. So for me, this is exciting in the sense that we found, I think another subset of patients and reduced again the amount of those seronegative or ALD patients that they're not actually seronegative, whether they are now anti SA antibody positive.
What I'm hoping is that we end up with a similar situation in RA and RA ILD to what we have probably with polymyositis, where gradually, gradually we find out that these people that we previously termed polymyositis actually have some other antibody definable disease. And that group shrinks down and down and down until it's almost nonexistent. So check out my further ACR twenty twenty six content RichardPaconway on Twitter and check out RheumNow for all the best ACR content from the whole meeting.
Are we so focused on helping our patients lose weight that we're forgetting about something equally important, their muscle? Hi, I'm Audrey Gibson, a physician assistant reporting for RheumNow from ACR Convergence twenty twenty six in Orlando. We've heard a tremendous amount about obesity, GLP-one medications, and weight reduction here at ACR. But today, I wanna talk about something that may not be getting enough attention. What happens to muscle strength and muscle mass in our patients with rheumatoid arthritis?
Abstract eighteen oh four presented by Diana Carrera Cruz and colleagues addresses that question. We know that rheumatoid arthritis is associated with chronic inflammation, decreased physical activity, altered body composition, and muscle loss. And here is something important. A patient can have obesity and still have very little muscle. The investigators examined two different conditions.
First is Dinopenic Obesity. These patients have excess body fat and reduced muscle strength, but their muscle mass is relatively preserved. The second is Sarcopenic obesity. These patients have excess body fat along with reduced muscle mass. Why does that distinction matter?
Because a patient may appear to have adequate muscle simply based on body size while actually experiencing declining strength or loss of lean tissue. And in rheumatology, that can translate into difficulty like getting out of a chair, climbing stairs, carrying groceries, or maintaining independence. This was a cross sectional study involving sixty one patients with rheumatoid arthritis. The investigators measured body composition using DEXA, evaluated hand grip strength, and assessed disease activity using a dash twenty eight. The average age of the patient was approximately 57 years and nearly ninety two percent were women.
The findings were interesting. Approximately twenty eight percent had obesity with preserved muscle strength and muscle mass. About twenty percent had dienopenic obesity, meaning reduced grip strength despite preserved muscle mass. And nearly half, forty nine percent, had sarcopenic obesity, meaning excess adiposity combined with reduced muscle mass. Now remember, this is a small selected population, we should not make generalizations.
But here's what caught my attention. Patients with obesity alone have an average grip strength of 23.4 kilograms, but those with DynaPedic obesity averaged only 12.2 kilograms and those with sarcopenic obesity averaged 14.5 kilograms. And these differences occurred despite no statistically significant difference in -twenty eight across the groups. Even more interesting sarcopenic obesity was independently associated with greater functional disability on a HAC DI after adjustment for age, sex, disease duration, and disease activity. The adjusted difference was approximately 0.35 points.
So even when accounting for inflammatory disease activity, the patients with reduced muscle mass experience greater disability. So what should we take away from these findings? First, BMI doesn't tell us the whole story. Two patients may have the same BMI but very different levels of muscle strength and function. Second, controlled inflammation doesn't necessarily mean preserved physical function.
We can have a patient with relatively low disease activity who is still struggling because of changes in body composition. And third, as we increasingly incorporate weight management strategies into our rheumatology care, we need to think about preserving that muscle. This is particularly relevant with growing use of GLP-one based obesity treatments. And it does remind us that weight reduction should not be our only goal. We should be asking about strength, mobility, and daily function.
We should encourage appropriate resistance exercise, adequate nutrition, and physical therapy when needed. And for selected patients, a more detailed body composition assessment may be helpful. Because ultimately, our goal isn't just a lower number on the scale, it's a patient who can move better, function better, and live better. I'm Audrey Gibson reporting from ACR Convergence twenty twenty six in Orlando. Follow RheumNow for more clinical insights and updates from the meeting.
Thanks.
Go to roomnow.live to see the full program and register today.
David Lu here as part of RheumNow's rheumatoid arthritis coverage from ACR convergence twenty six. I wanted to point out a poster, on the poster floor which looks at TriNetX data. And immediately when people say that nowadays, everyone gets a bit cautious, but I think this has been done quite well. And it really addresses a point that, has sometimes been missing from the discussion. What is that?
Well, it's about JAK inhibitor safety in younger adults. One of the real victims of, any loss of nuance around ace... Around, oral surveillance has been what happens to younger adults who might benefit from JAK inhibitors and the discussions, the nuances of discussions around starting a JAK inhibitor. And, you worry that, people might not be getting the best therapies that they could be because these conversations are difficult to navigate from many different directions. So this is exactly what this analysis looks at.
It looks at these big data, but looks at younger adults, 18 to 64, with rheumatoid arthritis starting therapy compares JAK inhibitors to TNF inhibitors, looks at cardiovascular outcomes, some new major adverse cardiovascular events, arterial cardiovascular events, VTEs, and and tries to see whether there's any signal there knowing that we haven't always seen our observations replicated in observational data. But what's very clear here is that there is no signal in younger adults, as far as this is concerned. So I think what what do we take away from that? And and look. There's some nuances with the data that I'm not gonna drag you through, but just to say that I think as much of the discussion has been there's been debate within the enriched, at risk population that oral surveillance targeted in terms of JAK inhibitor safety.
And, you know, that is... That's been well documented. Outside of that, and realistically, when you break down oral surveillance, outside of the patients who have actually had outright cardiovascular events in the past, you have to say that the risk is, very close to that what... In what you see with TNF inhibitors. And we've got to be very cautious about not disadvantaging those types of patients away from effective therapies knowing that we should keep the nuance, keep the balance and be aware of what the regulatory warning does show.
So for lots more on rheumatoid arthritis, you know where to go. Roomnow.com.
Hi. This is Bella Mehta from RoomNow reporting from ACR twenty six. I came across an interesting abstract. Abstract number 0616. What it's trying to do is figure out if patients with RA who also have fibromyalgia, are there certain things that can help us find these patients who have additional pain or additional symptoms which are consistent with fibromyalgia?
So, know, the fibromyalgia nineteen ninety criteria is much more restrictive than the twenty sixteen criteria. So more patients are now getting diagnosed because of the slightly more relieved criteria. So what these investigators did was try to figure out if, you know, making a... Or finding a difference between tender joint minus swollen joint, if that helps us distinct or find these patients. So back in the day, there was a study looking at this threshold of tender minus swollen joints, it was seven...
If there's seven joints which are more tender than just the swollen joints, that seemed to be something that can help figure out help figure out if patients have fibromyalgia. So, they now use the twenty sixteen criteria and, try to figure out if, patients... What's the difference in the tender and swollen joint count. So when they did that, around, you know, seven percent more patients were diagnosed with fibromyalgia using the slightly broader criteria. So it was twenty two percent in the nineteen ninety criteria versus twenty nine percent in the twenty sixteen criteria.
And, again, these are all RA patients who have an additional diagnosis of fibromyalgia with the new criteria. They also found that when the threshold of four, you know, tender minus swollen joint count, the threshold of four was applied, the sensitivity increased from point seven one to point seven six. But the specificity did go down from around, again, point seven to around 4.58. So what it tells me is that, again, we all know that when somebody has many, many tender joints, there's a high likelihood of central pain or fibromyalgia or one of those things. But this study gives you a rough sort of estimate or a rough thing that you can go off saying, if it's more than four, the difference in joint count for tender and swollen, you sort of wanna think if there is, you know, if there is another component to it.
Is this a definite checkpoint? Absolutely not. But it's something to help you start thinking about this. So, I I think, it's important for clinicians to take home that four four joint counts threshold, which is more tender than swollen, is helpful to find other pain syndromes, including fibromyalgia. With that, signing off.
This is Bella Mehta on RheumNow, and follow us more on Twitter, Bella underscore Mehta. Thank you.
Hi. It's doctor Arti Kavanagh from University of California San Diego coming to you for RheumNow. And I'm here at the ACR Convergence. First day of the meeting, really a packed meeting with a lot of great information already and a lot more to come still. A topic I'm going to talk about, and we're talking about themes, we're talking about just principles, to treat rheumatoid arthritis.
And the reason I picked this topic, well, it's a hot topic, and I think we've seen a lot more interest in this. We're talking about newer therapies, newer treatments, newer treatment algorithms for rheumatoid arthritis. Some of them, if you think of the risk benefit ratio, maybe they're a little bit riskier. So, would you want to have it for a population of patients where there's the greatest need? And as clinicians, I think we think maybe the greatest need is in the most refractory patients.
We've known forever in rheumatoid arthritis care that the more therapies you have tried, the more therapies you have failed, the more refractory you are. The less well you're going to do with the fifth therapy if you have been on four. We've known that since the days of just conventional synthetic DMARDs. What about now? What do we know about this?
Difficult to treat rheumatoid arthritis, the EULAR group has come up with a definition of that, which you can look up. It makes sense. It's a difficult concept, I think, for us clinicians. We all know the patients that we see in the clinic who are difficult to treat. We can identify them, but it's hard to write that down.
So what is this difficult to treat? There's an abstract, fourteen oh seven, which looked at this with an interesting side take, I believe, and that is we talk about difficult to treat RA. Well, how stable is that? What happens to people if you go to the clinic and you find a bunch of people who are classified as difficult to treat RA using the UR criteria? What happens to them over time?
So they looked at this in this abstract, and what they found was relevant to people who were interested in coming up with treatment algorithms and therapeutic studies for difficult to treat RA. What they found is about half the patients seemed to be stable in difficult to treat RA, meaning they were difficult to treat RA at subsequent time points. The other half were less stable. Some jerked right out, they were not in difficult to treat anymore. Some came in and out to various degrees.
Interesting question. If you were planning to treat difficult to treat RA patients, who would you pick? I think the first blush you might say, well, the ones who are in difficult to treat all the time, because they're the toughest, they're the most refractory, but maybe they're the ones more likely to be influenced by things like pain, and they may never respond to immunomodulatory therapies. But if you have those who come in and out, and the investigators looked at this, treatment didn't necessarily relate to them coming in and out difficult to treat. So, fascinating question.
It's one of those things that we all know what difficult to treat means when we go to the clinic, but how do you translate that into something where you can write it down and put it into a clinical trial? This is Doctor. Arti Kavanaugh coming to you from ACR Convergence twenty twenty six for RheumNow.
Hello. My name is Elena Jerns, and I'm reporting from Orlando, Florida. A lot of interest in JAK inhibitors in RA ILD at this meeting. I'm glad to see the studies because we certainly need more. It does seem that JAK inhibitors are helpful in our reality based on a small meta analysis which was published in 2024.
But we have so many JAK inhibitors now and we are often limited by insurance companies in what we can prescribe. But are they truly interchangeable? Are they truly safe and efficacious in our ALD? Well, this meeting had several relevant posters. So poster number four seventy eight by doctor Munoz detailed results of a retrospective observational study of baricitinib in eighty four patients with RAILD.
They demonstrated stability of PFTs and improvement in dyspnea throughout follow-up, and importantly the steroid use was decreased. We of course don't know how their trajectory was prior to the treatment from the abstract, but the improvement in symptoms and reduction in steroids is encouraging regardless. Poster number four forty nine by Doctor. Kikuchi and colleagues also demonstrated that the array ILD was stable and even improved based on lung ultrasound scores with treatment with JAK inhibitors. They didn't specify the JAK inhibitors, unfortunately.
In poster seven zero three, Doctor. Ortiz and colleagues looked at 43 patients from Spain treated with upadacitinib and found stability or improvement in lung function parameters and again symptoms of dyspnea. Despite these promising results, JAK inhibitors are still not widely used in our RAYALDEE as per poster number four two by Doctor. Sarmiento Monroy regarding real world treatment patterns in Array ILD. Their nested case control study from Spain showed that only three percent of patients with Array ILD were treated with JAK inhibitors, but eleven percent of patients with RA with no ILD at baseline were treated with JAK inhibitors.
Important safety signal for JAK inhibitor was accessed. I think the worry about cardiovascular safety precludes us often from prescribing JAK inhibitors in RA LD, as these patients are frequently dosed with many cardiovascular risk factors also. Poster number four forty one by Doctor. Kasiraj compared safety between JAK inhibitors and found that tofacitinib was associated with significantly higher risk compared to upadacitinib or baricitinib in terms of major cardiovascular events. And Doctor.
Kazero's study in poster four forty two found that signal as well tofacitinib but not upadacitinib was associated with higher risk of major cardiovascular events in a real world study. The multitude of studies of JAK inhibitors, and these are not even all the posters about them, support the use of JAK inhibitors in RYALD. Safety signals support going for baricitinib or upadacitinib in patients with RALD who have cardiovascular risk factors. And I would advocate for perhaps a randomized controlled trial, and specifically RALD using specific JAK inhibitors. It does seem like we're not using JAK inhibitors enough in RA ILD yet, but hopefully it'll change with more data.
Thank you.
Hi. It's doctor Janet Pope. I tweet under at Janet Bourdeaux. I'm here at RheumNow reporting on ACR twenty twenty six in Orlando, and it's a great meeting. I wanted to talk about people at risk for RA who are anti CCP positive, who gets RA, and also who might not get RA.
And the latter, patients, maybe we don't even have to follow them for very long. Who knows? So this is... The first abstract was 1834. So, again, this is the Leeds cohort for both of these abstracts.
So what they were doing was CCP positive, and they had MSK pain. So they might have had arthralgia. They might have had other MSK pain, and they were put on a protocol to be followed regularly, including by ultrasound. So a hundred and ninety three of these patients, which there were over four hundred and fifty, of those patients, a third of them had erosions. And by erosions, I mean by ultrasound, not by plain X-ray.
Where were the erosions? The areas that we try to teach you where erosions occur early. Fifth, MTP, lateral side, MCP, especially number two, and wrist. Also, the other area I like to tell patient... Tell trainees about is the owner style, but, distally, but they didn't talk about that one.
But fifth MTP, MCP, especially the second one, and wrist. So what did they find? These people that had an ultrasound erosion, not all of them progressed to clinical diagnosis of rheumatoid arthritis, and not all of them, the erosion stayed because this is ultrasound, not plain X-ray. But if you have these erosions at baseline, one or more, you had more severe RA, you were more apt to need biological DMARDs, and you were more apt to be difficult to treat. Not everyone progressed, and not everyone, got RA in the group that didn't have this either.
So that was the take home. Now the next abstract was, abstract 1835. And what the question here was, in this, pre RA or RA at risk, ACPA positive cohort of patients with, MSK pain, who... What would be the good predictors over the next five to ten years? Who is not gonna get rheumatoid arthritis?
So, again, they have some kind of pain, MSK, and they're CCP positive. They were on the protocol. And if you had, good predictors, three of five, eighty two percent did not progress over the next, five to ten years. There are four hundred and fifty patients followed in this group. So what were the good predictors?
They all were CCP positive. So if your CCP was pretty low, that was better. Negative rheumatoid factor, normal ESR, less than or equal to one tender joint, and no tenosynovitis on clinical or on imaging. So my question is, if I have a patient that has all those good predictors with a positive ACPA, if they had all five of them, none of them in the next five to ten years developed RA. Can I just say, I don't need to see you?
Call me if things change. I think at this point in time, I'd still be more apt to follow them regularly at least for a while, but this is really helpful to predict who will do well over time. Please follow our reporting at RheumNow. Thank you.
Hi. This is doctor Arti Kavanagh coming to you from ACR twenty twenty six Convergence for RheumNow. My perspective this talk is going to be on combination therapy, specifically combination therapy in rheumatoid arthritis. Fascinating topic that has a deep history. Based on the 80s, there were many animal models of rheumatoid arthritis which suggested that combinations of different targeted therapies is probably the way to go.
Thinking of TNF inhibition, IL-one inhibition, in animal models, that was fantastic. You not only saw additive benefit, you saw synergistic benefit. You saw the complete abrogation of inflammation and damage in animal models. Of course, as we all know, in humans the experience was much different. In studies that looked at TNF inhibition plus IL-one inhibition, and TNF inhibition with T cell inhibitor therapy with abetacept, the results were dismal.
There was not clinical benefit, but there was a readout, and that was increased infection. So since that time, and this is now going back to the early nineties, there's been black boxes that say do not combine biologic agents. Well, times are evolving, and thanks to collaboration with our colleagues in ulcerative colitis and a pivotal study called Vega that showed that combination of a TNF inhibitor, glimumab, plus an IL-twenty three inhibitor, gazelkumab, did what we had always hoped combination therapy would do, and that is additive benefit without additive toxicity. Now, rheumatoid arthritis has kind of lagged that a little bit. There are studies going on in ulcerative colitis, in IBD otherwise, in ankylosing spondylitis, in psoriatic arthritis.
Not so far in rheumatoid arthritis. I think we've still been a little bit gunshot. So there are a couple of abstracts at this meeting, small numbers of patients, one from Neuven, which had six RA patients, and this abstract, fourteen oh two, which looked at abetacept plus an anti CD38 monoclonal antibody, daratumumab. Three patients only, severe refractory disease. The results really kind of didn't knock your socks off, even though it's only three patients.
There was an improvement, and they are very refractory patients, and there didn't seem to be a lot of toxicity, but there was some. Daratumumab anti CD38 monoclonal antibody approved for certain kinds of cancer, but it's strong, and it's a strong therapy directed at cells bearing CD38, which is widely spread. Looking at these results, I would say I'm not sure that I'm excited about this particular approach, but I think it's great to see the idea of combination therapy opening up, and I think we're at the point where we'll see anecdotes such as these. In the Leuven study, TNF inhibitors and JAK inhibitors were combined, and it seemed to not have a safety signal. Of course, we need more patients, but I think we'll see that certain combinations get knocked out of the running early, and others need to be studied further in more rigorous study design.
So combination therapy may be coming back in rheumatoid arthritis. This is Doctor. Arti Kavanagh coming to you from ACR twenty twenty six Convergence for RheumNow.
Hi. I'm doctor Janet Pope or tweeting as, at Janet Brudeau. I'm here at RheumNow at ACR twenty twenty six in Orlando, Florida. I wanted to talk about SNPs and snippets in interstitial lung disease related to our SARDs. So I'm gonna talk about three posters, 0019, 0037, and 0025.
And they have some mechanisms of action in common and different pathways. So the first one, zero zero one nine, was looking at t l one a in sarcoidosis and looking at the fibrosis and sarcoidosis, which could be systemically all over, including in the lungs. And t l one a is a target for some, drug trials for pulmonary, interstitial lung disease. So what they found was t l one a was, abnormal in the myeloid cells and eventually in the cells that became and made granuloma. And so it would look like it's something important on causation.
And what they found was t o one a was affecting TNF, I o one beta, I o six, and I o 17. And they're all cytokines you're very familiar with in inflammatory arthritis as a for instance. So I think this might mechanistically give us an idea of upstream and downstream, areas for interstitial lung disease or fibrosis that we might be able to target. The next one was looking at 37, the poster. It was looking at scleroderma ILD and they wanted to look at correlations with baseline FVC, so forced vital capacity.
It was actually FVC percent predicted. So they did a whole array on sixty patients with scleroderma ILD and nineteen with scleroderma, no ILD, and they kinda match those patients. And what they found was predictive at baseline, but not of worsening over time. So both an elevated k... KL six and an abnormal ICAM one were both important for low FVC at the beginning.
However, the holy grail in scleroderma ILD is predicting who might have upregulated things that might actually might actually show that we can predict what's going to happen in scleroderma ILD. The final one was from UCSF, it's 25 and it was looking at some similarities comparing and contrasting SARD ILD and progressive pulmonary fibrosis, IPF. So it's been known to them, and I guess now to me, is that short telomeres are a big deal in, IPF that they're often present, and I think they're correlated with worth... Worse IPF. And some people are even ordering telomeres more for research purposes.
So what they wanted to look at was senescence with epithelial remodeling that would be bad remodeling. And what they found was that DNA damage was quite common patients with ILD and the SARDs, the systemic autoimmune rheumatic diseases, and also in IPF. Why did I choose this poster is because I think it's yet another pathway to say if there's abnormal senescence, is there ways of changing that that we could modify or decrease the chance of someone with SARD ILD going to fibrosis? So I hope these snippets that I, got from posters will be helpful to you in understanding ILD of the SARDs. Thank you.
David Lu here covering ACR conversions 2026, and some very interesting stuff, about Carti and R. A. That's come out at this meeting. It's been perhaps a little less enthusiastic than what we've seen for CAR T and lupus, CAR T and Sjogren... So CAR T and scleroderma, CAR T and and myositis.
But nevertheless, it's understandable that manufacturers are looking at RA. They can see a really big potential market there. They can see that there's an established pathway to therapies. There are already plenty of expensive therapies there and that there are issues and that really it'd be nice to be able to offer people options in RA. Yet at the same time they've got to compete with existing therapies and that's the tough balance of it.
I think one thing which has we've seen, well we've seen we've seen at this meeting but also seen hyped up in general has been actually the COMPARE study which was published in Nature Medicine a couple of months ago but also was back again at this meeting. It's from Germany, not Gaelscheid, but a broader group, only six patients. But I think it gives you an idea about some of the sticking points in trying to navigate this story in rheumatoid arthritis. So firstly, it's conventional CAR T and comes with all the challenges that we see there. Secondly, in order to make it a valuable interpretation of this, it's highly refractory rheumatoid arthritis patients.
You need to have failed at least one biologic actually multiple in practice. And so we're seeing this in the way that studies recruit as well and and I guess that makes it harder to interpret. It's harder to apply our general conventions to this. What are what are we expecting? Maybe that's actually part of the game here that, and to some extent any gain is better.
So anything that gives you efficacy in these tough patients is clearly promising and there's appropriate a lot of interest but you know you break through both what we've seen here and in the paper. Actually you know it's not necessarily going to be the cure. It's not a cure for everyone. It's not it's not a long term panacea for everyone. We're seeing people within the year who get a response and then things bounce back again.
You have to ask yourself how much of that was lymphodepletion? How much of that was something else versus actually true effect. We're seeing a lot of things creep up. I guess some of the other things like antibody titers, it's hard to know how to interpret. So, as we start to see bigger numbers, we're going to start to be able to ask ourselves questions about what type of patients to select.
And that's going to be all well and good. But I think we need to just, at this point in time for rheumatoid arthritis, set appropriate expectations. If we're going to use CAR T in this disease know that it's not going to cure it's not going to be for everyone definitely. The people who it's for it's not necessarily going to cure them all either. We're going have to work through all the same problems with CAR T that we are working through with lupus and scleroderma and myositis.
So for plenty more about RA and plenty more about CAR T, you know where to go. Rheumnow.com.
Hello, everyone. I'm Richard Conway from Dublin, Ireland reporting for RheumNow from ACR twenty twenty six. I'm here to talk to you today about an interesting abstract from Sunday's poster session. This was abstract number four seventy five by Rocolia et al. This study, I'm calling it not seronegative or a ILD, but the actual title is Association of Novel Autobahn Antibodies with ILD and aerosive Disease in Seronegative Rheumatoid Arthritis.
And first of all, that aerosive disease part, I'm not going to talk about it. It wasn't that interesting what they found in that area, in my opinion. But the other half of it was. So seronegative rheumatoid arthritis is a term I am not a huge fan of in general. What we generally mean is it's negative for rheumatoid factor and CCP.
But as we'll see with this study, maybe it's not actually seronegative at all. So to me, it's more like these patients are patients with RA in search of their autoantibody, which we either can't find or don't have availability of the tests which demonstrate us. And rheumatoid arthritis related interstitial lung disease, we know is quite strongly associated with the autoantibody nature of disease, so associations with both rheumatoid factor and CCP. So that being the case, I like the existence of seronegative RA ILD even less. It just doesn't jive right with me.
So as I said, I think generally these patients who have oral ALD and they're negative for rheumatoid factor and CCP, my suspicion is that there probably are other autoantibodies there that we can't pick up yet. And great, these authors have found some. So they included forty eight seronegative rheumatoid arthritis patients. Now there's only ILD in four of those. So we're dealing with a relatively small sample size here, but still I think the results are interesting.
So these authors looked at two novel autoantibodies, what they've termed them. I guess autoantibodies that we don't check as commonly because they're not brand new things. So first of these was anti SA antibody and the second was anti CAR P. And they looked at those antibodies, saw how frequent they were in patients with and without ILD. So anti SA is the interesting one.
So that was positive in forty two point nine percent of patients with ILD and in only two point four percent of those without ILD. So greatly more common in those patients with ILD. The anti CAR P antibodies in contrast were equally present in those with and without ILD being found in eight point three percent of both sets of patients. So that's interesting. So for me, this is exciting in the sense that we found, I think another subset of patients and reduced again the amount of those seronegative or ALD patients that they're not actually seronegative, whether they are now anti SA antibody positive.
What I'm hoping is that we end up with a similar situation in RA and RA ILD to what we have probably with polymyositis, where gradually, gradually we find out that these people that we previously termed polymyositis actually have some other antibody definable disease. And that group shrinks down and down and down until it's almost nonexistent. So check out my further ACR twenty twenty six content RichardPaconway on Twitter and check out RheumNow for all the best ACR content from the whole meeting.
Are we so focused on helping our patients lose weight that we're forgetting about something equally important, their muscle? Hi, I'm Audrey Gibson, a physician assistant reporting for RheumNow from ACR Convergence twenty twenty six in Orlando. We've heard a tremendous amount about obesity, GLP-one medications, and weight reduction here at ACR. But today, I wanna talk about something that may not be getting enough attention. What happens to muscle strength and muscle mass in our patients with rheumatoid arthritis?
Abstract eighteen oh four presented by Diana Carrera Cruz and colleagues addresses that question. We know that rheumatoid arthritis is associated with chronic inflammation, decreased physical activity, altered body composition, and muscle loss. And here is something important. A patient can have obesity and still have very little muscle. The investigators examined two different conditions.
First is Dinopenic Obesity. These patients have excess body fat and reduced muscle strength, but their muscle mass is relatively preserved. The second is Sarcopenic obesity. These patients have excess body fat along with reduced muscle mass. Why does that distinction matter?
Because a patient may appear to have adequate muscle simply based on body size while actually experiencing declining strength or loss of lean tissue. And in rheumatology, that can translate into difficulty like getting out of a chair, climbing stairs, carrying groceries, or maintaining independence. This was a cross sectional study involving sixty one patients with rheumatoid arthritis. The investigators measured body composition using DEXA, evaluated hand grip strength, and assessed disease activity using a dash twenty eight. The average age of the patient was approximately 57 years and nearly ninety two percent were women.
The findings were interesting. Approximately twenty eight percent had obesity with preserved muscle strength and muscle mass. About twenty percent had dienopenic obesity, meaning reduced grip strength despite preserved muscle mass. And nearly half, forty nine percent, had sarcopenic obesity, meaning excess adiposity combined with reduced muscle mass. Now remember, this is a small selected population, we should not make generalizations.
But here's what caught my attention. Patients with obesity alone have an average grip strength of 23.4 kilograms, but those with DynaPedic obesity averaged only 12.2 kilograms and those with sarcopenic obesity averaged 14.5 kilograms. And these differences occurred despite no statistically significant difference in -twenty eight across the groups. Even more interesting sarcopenic obesity was independently associated with greater functional disability on a HAC DI after adjustment for age, sex, disease duration, and disease activity. The adjusted difference was approximately 0.35 points.
So even when accounting for inflammatory disease activity, the patients with reduced muscle mass experience greater disability. So what should we take away from these findings? First, BMI doesn't tell us the whole story. Two patients may have the same BMI but very different levels of muscle strength and function. Second, controlled inflammation doesn't necessarily mean preserved physical function.
We can have a patient with relatively low disease activity who is still struggling because of changes in body composition. And third, as we increasingly incorporate weight management strategies into our rheumatology care, we need to think about preserving that muscle. This is particularly relevant with growing use of GLP-one based obesity treatments. And it does remind us that weight reduction should not be our only goal. We should be asking about strength, mobility, and daily function.
We should encourage appropriate resistance exercise, adequate nutrition, and physical therapy when needed. And for selected patients, a more detailed body composition assessment may be helpful. Because ultimately, our goal isn't just a lower number on the scale, it's a patient who can move better, function better, and live better. I'm Audrey Gibson reporting from ACR Convergence twenty twenty six in Orlando. Follow RheumNow for more clinical insights and updates from the meeting.
Thanks.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.